Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.

Cancer Chemother Pharmacol · 2017 · PMC5403874 · PMID 28391355

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

near-significantno p-value reported

Moreover, age, metastasis, co-infusion of Dex with L-OHP and albumin and AST levels, which were significant or near-significant factors in group comparisons of patient backgrounds, were not identified as significant risk factors.

also in 2,306 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.